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Abstract—In case of physiological related researches the ap-
propriate adjustment of the parameters of the mathematical
models describing biological phenomenons is a crucial issue.
These models are essential in many research field such as the
personalized health care or the control of physiological processes.
Despite the available identification techniques there is no general
solution in those cases where the mathematical model is given, but
highly nonlinear in order to capture the main dynamical attitude
of the physiological processes to be described. One of our aims
was to develop such a general nonlinear identification framework
which is flexible, can be easily used and supports the identification
of these kind of models. We defined different metrics to measure
the performance of the developed system. From the other hand,
our goal was to successfully realize the identification framework
in case of tumor growth beside anti-angiogenic treatment which is
essential in our future work in order to validate the performance
of advanced control algorithms. The results show that the
nonlinear identification framework performed well in this case,
since the predefined requirements from the applied metrics points
of view were satisfied in all cases.
Index Terms—Identification, Nonlinear Least Mean Square
Method, Tumor Growth, Tumor Model Identification
I. INTRODUCTION
Targeted Molecular Therapies (TMT) represent an advanced
treatment opportunity beside the well known classical cancer
therapies as radiotherapy, chemotherapy and surgical inter-
vention. The TMTs – based on different drugs and/or other
substances – are used to eliminate the tumor growth and spread
in the body. TMTs interfering with specific molecules which
play important roles in the physiological processes concerning
to the growth, progression and spread of the cancer. Thus the
main aim of TMTs is the inhibition of certain physiological
processes and not to – directly – kill the tumor itself. Although,
in many cases the inhibition of a specific process leads to
the devastation of cancer cells. The main advantages of using
TMTs are the limited side effects and the more focused therapy
compared to the conservative treatments. Several TMTs exist,
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albeit, the most important ones are the apoptosis inducers,
signal transmission inhibitors, gene expression modulators and
anti-angiogenic therapies [1].
One of the frequently applied TMT is the anti-angiogenic
therapy [1]. The core concept in this case is to inhibit the
growing of the supplying vasculature of the cancer concourse.
It is known, that the supplying vasculature is needed in
order to provide the oxygen and nutrients after the tumor
grows beyond a certain volume due to the limited efficacy
of local diffusion. Diffusion itself – after a given volume –
is not able to satisfy the requirements of further growth from
nutrition point of view and to maintain the reached size. By
blocking the formation of new blood vessels the size of the
cancer concourse can be decreased or kept below a given
level which is tolerable from the human body point of view.
Normally, the angiogenic processes are infrequent in healthy
adults, but frequent concerning to tumor growth. By inhibiting
this process only limited side effects occur compared to the
conservative therapies.
The angiogenic processes are regulated by anti- and pro-
angiogen factors. The most important pro-angiogen factor is
the vascular endothelial growth factor (VEGF). The VEGF
controls the endothelial proliferation – the reproduction of
endothelial cells from which blood vessels are formed – which
makes it excellent target for such inhibitor therapy [1]–[3].
In clinical practice, three approaches are used for drug de-
livery in case of anti-angiogenic therapy: bolus doses therapy
(BDT), metronomic low dose therapy (MLDT) and continuous
infusion therapy (CIT) [4]. In case of BDT the amount of the
injected drug is the maximum dose which can be tolerated
by the human body. Between the boluses there is no anti-
angiogenic kind drug injection. The main disadvantages are the
frequently occurring side effects and the remaining tumor cells
may become resistant to the therapy due to their fast evolution
and proliferation [5]. MLDT provides a better alternative at
which the anti-tumor drugs are delivered in minimal dosage
based on predefined schedule over longer periods [6]. The in
silico- and animal-experiments have shown that application of
CIT protocol can be the most effective treatment among the
current anti-cancer therapies [7]–[9]. Albeit, to realize the CIT
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protocol in practice as a personalized therapy precise models
are indispensable. These models are also needed in order to
validate the performance of advanced control algorithm in a
personalized manner which promise a better outcome for the
individuals compared to today’s medical protocols.
To bridge this problem the most straightforward solution
from control engineering point of view is to develop an
identification process via the parameters of the existing math-
ematical models – which focus to the given phenomena –
can be adjusted. In this way instead the expensive clinical
trials a large population of virtual patients can be realized
and the treatments coming from new medical protocols or the
performance of the advanced control algorithms in this regard
can be validated in silico before their validation in clinical
environment. Accordingly, one of our goals was to develop
such an identification framework which is able to deal with
the afore mentioned issues, but also it is general and can be
used regardless the physiological processes to be described
and the mathematical model to be identified.
The paper is structured as follows: first, the applied tumor
growth model is introduced. After, the developed identification
framework is presented. In Sec. IV., we introduced the applica-
bility of the identification framework in case of the introduced
tumor growth model. Finally, we present our findings.
II. APPLIED TUMOR GROWTH MODEL
We intended to use a well-known model in this regard which
became a standard on the research field in the recent years.
Due to we decided to apply the Hahnfeldt model [10] which
describes the tumor growth beside angiogenic inhibition. The
model is able to describe the dynamics of the growth of the
tumor and the supporting vasculature as follows:
x˙1(t) = −λ1x1(t) log
(
x1(t)
x2(t)
)
, (1)
x˙2(t) = bx1(t)− dx2/31 (t)x2(t)− ηx2(t)g(t) , (2)
g˙(t) = −λ3g(t) + u(t) , (3)
where the x1(t) mm3 is the tumor volume and x2(t) mm3
is the volume of the supporting vasculature. The g(t) mg/kg
describes the antiangiogenic inhibitor serum level in time. The
model’s output is the x1(t) which is the only measurable
state. The original model parameters were adjusted based on
mice experiments (tumor: Lewis lung carcinoma, inhibitor:
endostatin). These parameters are the following: λ1 = 0.1921
1/day, b = 5.851 1/day, d = 0.00871 1/(mm2 day), η = 0.66
kg/(mg day) and λ3 = 1.31 1/day [10] .
The tumor growth model contains unfavorable mathematical
properties due to the phenomena which is described by it. The
model contains nonlinearities and nonlinear coupling between
the states. Moreover, strong limitations make the handling of
the model challenging, namely x1(t), x2(t) > ∀t (t > 0) and
feasibility problems can be occurred due to the log
(
x1(t)
x2(t)
)
term in (1) – which may causes (0/0) kind singularity, when
x1(t) and x2(t) are equal to zero. Further, if x1(t) and x2(t)
are close to zero numerical stability problems can be appeared.
It has to be mentioned that the Hahnfeldt model is a general
model. Namely, it is appropriate to simulate tumor growth
beside angiogenic inhibition regardless the type of the tumor
and inhibitor. Furthermore, despite it was developed by using
the considerations based on mice experiments, it can be used
to describe the state of the human being as well after the
appropriate adjustment of parameters of the model.
III. IDENTIFICATION FRAMEWORK
We have built a convenient identification framework in
the Mathworks’ MATLAB system based on the so-called
Nonlinear Least Squares Optimization (NLSO) method [11]–
[13]. Naturally, this framework is general, thus it can be used
in case of numerous nonlinear model identification problem.
During the realization we applied the MATLAB embedded
NLSO algorithm. This algorithm – via lqsnonlin function –
is able to solve nonlinear least-squares curve fitting problems
in the following form:
min
Ω
‖f(Ω)‖22 = min
Ω
(
f1(Ω)
2 + f2(Ω)
2 + ...+ fn(Ω)
2
)
,
(4)
where f(Ω) is the objective function to be minimized and
Ω is the parameter vector to be identified. Albeit, instead of
computing the sum of squares the implemented lsqnonlin
function requires a user-defined vector valued function [13].
We considered a difference based objective function for the
NLSO process in the following form:
f1(Ω) =
√
(z− zˆ(Ω))2 , (5)
where z is the measured data and zˆ(Ω) is the simulated
data based on the in silico experiments. We have tried other
objective functions as well (absolute error function, norm-
based functions, and others, but we experienced that (5)
provided the best achievements according to the predefined
metrics).
Consequently, (4) has to be modified accordingly (5) as
follows:
min
Ω
‖f(Ω)‖22 = f1(Ω)2 . (6)
Which makes the developed framework easy-to-use is the
implementation of the modeling environment. Each model to
be identified has to be realized graphically in SIMULINK,
however, the identification process (via the lsqnonlin algo-
rithm) is running from the MATLAB framework. In order
to make these sub-systems compatible we developed different
intermediate layers which doing the data synchronization and
matching. The structure of the identification framework can
be seen on Fig. 1.
In accordance with Fig. 1. the operation of the system can be
decomposed into three sub-systems: (i) initialization process,
(ii) operation of the NLSO framework and (iii) adjusting the
model parameters.
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Figure 1. The core structure of the identification framework
During the initialization process all initial data have to be
loaded as follows:
• NLSO related initialization: stopping criteria, type of the
lsqnonlin algorithm and boundaries (Ωub, Ωlb) of the
model parameters. We predefined the following stopping
criteria: MaxIter – maximum number of allowed iter-
ations, FunTol – termination tolerance on the function
value, StepTol – termination tolerance on the maximum
step distance. All of the others were considered with
their default values. We applied the following options:
O = [MaxIter,FunTol,StepTol,defaults] = [600, 1e −
12, 1e − 12,defaults], where defaults mean the not pre-
defined options. We selected the trust-region algorithm
[14] to execute the NLSO process. Ωub upper and Ωlb
lower parameter boundaries (vectors) also have to be
predefined.
• Ωinit initial model parameters.
• Parameters of SIMULINK environment. These are the
x(0) initial values of the model, T sampling time (has
to be the same as the sampling of the z measurements),
MaxStepSize (we applied MaxStepSize=1), parameters of
the input (piecewise or continuous depend on circum-
stances of the measurements).
The operation of the iterative NLSO framework can be
summarized as follows:
• Based on the initialized data the zˆ(Ω) occurring via the
realized simulation environment.
• Assessment is done according to the predefined metrics
based on (5) to determine the goodness of the occurred
zˆ(Ω).
• Examination of the stopping criteria. If one of the stop-
ping criteria is satisfied than the iterative operation of the
NLSO framework terminates. Else, a new cycle is started.
The result of the NLSO based nonlinear identification
process is the adjusted Ω parameter set. The adjusted Ω is
that parameter set with which the zˆ(Ω) simulated values are
the closest to the z measurements.
IV. IDENTIFICATION OF THE MODEL
The adjustment of the parameters of the model was done
by using measured data. The measurements coming from
mice experiments (species: C57BL/6) at which C38 colon
adenocarcinoma was implanted subcutaneously. The applied
angiogenic inhibitor was bevazicumab [15]. The mice were
divided into control group and case group accordingly the
original goal of the investigation. The case group received
inhibitor intake (injection) at each day during the treatment
(the amount was 1/18 mg/kg). The control group received
one injection at the beginning of the treatment (the amount
was 10 mg/kg) concerning to the existing medical protocols.
We had 3−3 measurements in the control and the case groups,
respectively. In both cases, the experiments were 10 days long,
thus, each measurement contains 10 data points [15], [16].
The original – literary – model parameters were adjusted
based on measurement data by using Lewis lung carcinoma
and endostatin inhibitor [10]. If the goal is to use arbitrary data
source all model parameters have to be identified. Our goal
was to adjust the Ωi = [λ1,i, bi, di, ηi, λ3,i]> model parameter
set from (1)-(3) by using the above detailed method.
During the identification we considered the followings re-
gard to the applied initial parameter set, initial state values,
initial parameters of the simulation framework and applied
boundaries in both (control and case groups) cases:
• Ωinit = [λinit, binit, di, ηi, λ3,i]> =
[0.1921, 5.851, 0.00871, 0.66, 1.31]>. Namely, the
Ωinit initial parameter set was the same as the literary
parameters accordingly [10]. This was a reasonable
choice, thus these are validated and the numerical values
are almost in the middle of the target range (bounded by
Ωlb and Ωub).
• The initial values of x1(t1) and x2(t1) in all cases
were the same as the initial values of the belonging
z(t1), namely, x1(t1) = x2(t1) = z(t1). Although, the
third initial state (g(t1)) was considered as zero. As it
was detailed above, the u(t1) initial inhibitor intake was
different in the case group (1/18 mg/kg at each day) and
control group (10 mg/kg at the beginning of the therapy).
• The applied lower and upper boundaries
were Ωlb = [0.05, 2.5, 0.001, 0.1, 0.01]> and
Ωub = [1.1, 10, 0.04, 2.1, 0.9]
>, respectively – according
to our previous researches these are appropriate ranges
in case of this tumor type and mice model [15].
The effectiveness of the identification process was measured
by three quality metrics. Each metric represents an other type
of quality and by applying both of them provides a full picture
about the goodness of all identified model. These metrics
are usually used regard to the assessment of identification of
physiological models [17]–[19].
The first one was the mean percentage variance accounted
for (VAF) [18], [19] in the form of
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VAFmean = mean
((
1− var(z− zˆ)
var(z)
))
× 100% , (7)
where z is the measured data and zˆ is the identified model
output at given appropriate time instance. If z and zˆ are equal
then the VAF parameter is 100% – in case of differences
between them the VAF is lower. The second applied metric
was the well-known root mean square error (RMSE) [20] in
the following form:
RMSE =
√
(z− zˆ)>(z− zˆ)
N
, (8)
where N is the number of samples of the measured data.
The last metric measures the fitness of the model by using the
simple fit metric (SFM) [18] in percentage. The SFM can be
calculated in the following way:
SFM =
(
1−
√
(z− zˆ)>(z− zˆ)√
(z− z¯)>(z− z¯)
)
× 100 , (9)
where z¯ = mean(z). If z = zˆ then the SFM parameter is
100% – else, the SFM is lower.
The gray box based nonlinear identification process beside
tight lower and upper bounds can be considered successful if
the VAFmean is not lower than 90%, the difference between
z and zˆ is not higher than 10% at each compared data point
and this reflects in the RMSE value and the SFM is higher
than 75% [17], [19].
As aforesaid, we had 3−3 measurements (both with 10−10
data points) regard to the control and case groups, each data
point represented 1 day. Due to in the simulation environment
T sampling time was set to T = 1 and all simulations provided
a 10 virtual days long simulated zˆ(Ω) data vector.
The results of identification concerning to the control group
can be seen on Fig. 2 whereon blue stars represent the z
measurement vector and the red line is the linear interpolation
between the zˆ simulated data points produced by the identified
model beside the applied Ω adjusted parameter set. As the
results shown that the identification process was successful
and provided acceptable results. In the second case a higher
deviation appeared between z and zˆ mostly due to the different
distribution of the data points. The upper part of Table I.
shows the results of the numerical assessment based on the
predefined VAFmean, RMSE and SFM metrics. According to
the VAFmean low variance occurred in the difference between
the z and zˆ. Although, the numerical values regard to the
RMSE metric seem high, but by taking into consideration the
magnitudes of the measurements the results were satisfying.
The SFM metric strengthen the previous results, namely, the
identification framework provides the best fitting in the first
and third cases.
Figure 3. shows the results of identification regarding to the
case group (blue stars represent the z measurement vector and
the red line is a linear interpolation between the zˆ simulated
data points produced by the identified model beside the applied
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Figure 2. Results of identification based on the control group data
Ω set). According to the diagram, the identification framework
performed with lower accuracy, mostly because of the daily
injections (1/18 mg/kg on each day) which was a higher
external load than the previous case. Although, in all cases
the results were acceptable and the identified models provided
appropriate outcomes. The numerical values of the applied
metrics can be seen in the bottom part of Table I. According to
the VAFmean low variance appeared in the difference between
the z measurements and zˆ simulated values. The RMSE and
SFM values shown that the value of the error was higher and
the fitting of the identified model was less accurate than the
previous case. Although, both values were acceptable respect
to the magnitude of z.
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Figure 3. Results of identification based on the case group data
Table I
RESULTS OF THE IDENTIFICATION: CONTROL AND CASE GROUPS. EACH
COLUMN REPRESENTS A GIVEN CASE
.
Control Group
VAFmean 98.6810% 95.2147% 99.9494%
RMSE 486.9614 394.7545 37.0242
SFM 82.8796% 67.3902% 96.6476%
Case Group
VAFmean 97.5985% 98.1631% 99.3287%
RMSE 815.7506 198.7766 42.6905
SFM 76.8989% 79.7959% 87.7860%
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V. CONCLUSION
In this paper we described a convenient nonlinear identi-
fication framework which can be used concerning to phys-
iological model identification. We systematically introduced
the operation of the developed system and the applied metrics
for the assessment. The other aim of the paper was to adjust
the parameters of a well-known tumor growth model beside
angiogenic inhibition via the developed process. From the
results it is clear that the nonlinear identification framework
performed well in this case, since the predefined requirements
from the applied metrics points of view were satisfied in
all cases. One of the main challenges was the low number
of samples in the individual measurements. This limitation
is a consequence of the tolerance of the mice respect to
given higher tumor volume and the strict rules of the animal
experiments due to ethical restrictions. In our future work we
will improve the introduced framework in order to increase
the accuracy of the identified model. Moreover, we are going
to investigate the performance of the developed tool by using
measurements in which more data points are available.
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